The role of ras genes in human mammary carcinogenesis remains undefined. Ras mutations are rare in breast carcinomas (Rochlitz et al., 1989) and gene amplification has not been recorded, but there are conflicting observations (reviewed by Field ) of ras protein expression. Hyperexpression has often been recorded (Spandidos & Agnantis, 1984; Ohuchi et al., 1986; De Bortoli et al., 1985; Clair et al., 1987; Fromowitz et al., 1987) , but some immunocytochemical studies with the antibodies RAP-5 (Ghosh et al., 1986 ) and Y13-259 (Candlish et al., 1986; Walker & Wilkinson, 1988) have found no increased reactivity in carcinomas compared with benign parenchyma. Walker and Wilkinson (1988) suggested that expression in carcinomas was actually less than in normal parenchyma. Some of the discrepancies may reflect methodological differences. Conclusions from immunocytochemical data, for example, have been clouded by the now proven nonspecificity of RAP-5 (Robinson et al., 1986; Rochlitz et al., 1988; Samowitz et al., 1988; Gutheil et al., 1989) . Interpretation of biochemical measurements of ras mRNA or protein is confounded by inclusion of many different cell types in the tissue homogenates analysed.
In this study we have used the pan-ras antibody Y13-259 (Furth et al., 1982) . It is a well characterised rat monoclonal IgGj, (Lacal et al., 1986) , and when bound to its epitope, blocks the interaction of p21 ras with its potential downstream effector molecule, GTPase activating protein (GAP) (Srivastava et al., 1989) . This epitope does not survive conventional aldehyde fixation well, but cryostat sections fixed in acetone (which conserves the epitope) are unsuitable for critical assessment of breast histology. Excellent preservation of morphology and Y13-259 immunoreactivity are obtained, however, in paraffin-embedded tissue fixed in periodatelysine-paraformaldehyde (PLP) and its dichromate derivative (PLPD) (Going et al., 1988a) . These fixatives preserve membrane localisation of p21 ras in transformed rodent fibroblasts expressing mutant p21 ras. No studies of human carcinoma have so far demonstrated the expected localisation of p21 ras to the plasma membrane (Going et al., 1988a; Williams et al., 1985; Chesa et al., 1987; Walker & Wilkinson, 1988 (Buehring & Jensen, 1983) to identify areas of abnormal parenchyma.
Fixation and processing Tissues were fixed in periodate-lysine-paraformaldehyde-dichromate (PLPD), processed to paraffin, and 4 tm sections immunostained with monoclonal antibody Y13-259 (obtainable from Oncogene Science) and an avidin-biotin detection system (Dako), together with appropriate controls (Going et al., 1988a) . Morphological assessment of haematoxylin and eosin sections, including the diagnosis of special types of carcinoma, was by published criteria (Page & Anderson, 1987) Oestrogen receptor status Oestrogen receptors were measured as previously described (Hawkins et al., 1981) in homogenates made from tissue taken adjacent to the site selected for histology.
Results
Normal breast p21 ras expression in normal epithelium was weak and heterogenous. On semiquantitative assessment there was no difference in expression between ductules of terminal duct lobular units (TDLU) , small extra-lobular ducts and larger ducts, and as both ductal and lobular carcinomas are thought to arise from TDLU (Wellings & Jensen, 1973) , the epithelium of TDLU was selected to represent normal parenchyma in subsequent comparisons. Expression was the same in morphologically normal TDLU of women with cancer and women with benign changes only, but TDLU of women younger than 45 (the median age in our study population) expressed p21 ras more strongly than those of women aged 45 or over (P<0.01).
Myoepithelial cells in common with epithelial cells showed no difference in expression between large ducts, small ducts and TDLU, but overall expression in myoepithelial cells was consistently stronger than in epithelial cells (P <0.001; Figure la) . Immunoreactivity with Y13-259 was also strong in vascular smooth muscle, and occasionally in normal endothelial cells (Figure lb) . Epithelium lining cysts Apocrine cyst epithelium was usually positive for p21 ras immunostaining, but some different patterns of ras expression were seen. In most cases there was distinct membrane localisation, usually apical, but in some cases baso-lateral ( Figure Ic) . In contrast the flattened simple epithelium of many cysts was consistently negative for p21 ras (P <0.0001).
Hyperplastic and atypical epithelium There was progressively stronger and more extensive p21 ras expression from normal through hyperplastic and atypical epithelium to non-invasive carcinoma. Figure 2 presents In many carcinomas in which p21 ras was strongly expressed, cells undergoing apoptosis and cells in areas of confluent necrosis lost Y13-259 immunoreactivity ( Figure  Id) . This was also true for cells retaining some nuclear chromatin at the edge of areas of confluent necrosis, and there was usually a sharp transition from expression to nonexpression.
Cellular location ofp21 ras In almost all carcinomas, invasive or non-invasive, p21 ras expression was intracytoplasmic ( Figure Id) . A few cases showed membrane as well as cytoplasmic positivity, and one lobular invasive carcinoma was unique in this human material in showing dominant membrane localisation (Figure le) . By contrast, there was almost exclusive membrane expression in cells of a rodent fibroblast tumour expressing human Ha-ras (Going et al., 1988a ; Figure 1 f In these studies p21 ras was found predominantly in the cytoplasm. It is noteworthy that similar cytoplasmic location has also been observed in several previous studies of p21, using a variety of antibodies, in non-neoplastic human or rodent tissues and some human tumours (Williams et al., 1985; Bizub et al., 1987; Chesa et al., 1987; Furth et al., 1987; Ward et al., 1989; Going et al., 1988a; Papadimitriou et al., 1988; Tiniakos et al., 1989; Koutselini et al., 1990) . Indeed, distinctive membrane localisation is exceptional in human and normal rodent tissues. The classical perception that the majority of p21 molecules are anchored to the plasma membrane derives -we believe exclusively -from studies of transformed cells, usually rodent fibroblasts (Willingham et al., 1980; Willumsen et al., 1984; Hancock et al., 1989) . Several explanations can be offered for this apparent discrepancy.
First, it is possible that the observed cytoplasmic location is artefactual, resulting from changes effected during fixation. Although this trivial interpretation is commonly proposed, it is clearly erroneous. PLPD, the fixative used here, was developed because of its effectiveness in stabilising membrane-linked epitopes (Holgate et al., 1986) . In our hands p21 ras was not displaced from the membrane of transformed rodent fibroblasts by delayed fixation, and the membrane localisation which was observed in the human breast was restricted to specific minority cell types (for example apocrine epithelium).
A second trivial explanation is that Y13-259 detects cytoplasmic epitopes other than p21 ras. Obvious candidates would be other members of the expanding ras gene superfamily which share many common amino acid sequences with ras proteins, but may lack plasma membrane localisation (Bourne et al., 1991) . The specificity and selectivity of Y13-259 for p21 ras has been repeatedly demonstrated however, in both immunoblotting and immunocytochemical contexts (Furth et al., 1982; Robinson et al., 1986; Ward et al., 1989) . It detects Ha-Ki-and N-ras p21s, which have identical amino acid sequence in and around the six critical positions that define the antibody binding site. Single substitutions involving any of these amino acids are known to diminish antibody binding more than 1,000-fold (Sigal et al., 1986) , and such substitutions occur in all other members of the superfamily (Chardin & Tavitian, 1986; Lowe et al., 1987; Didsbury et al., 1989; Pizon et al., 1989; Nimmo et al., 1991) .
A third possibility is that biologically effective p21 ras is indeed restricted to the plasma membrane of breast epithelium, but is present in relatively small amounts, the larger quantities detected in cytoplasm representing either inactive precursors or degradation products. Ras proteins are initially synthesised as 23,000 kd molecules (called p23), that undergo processing in the cytoplasm before anchorage to the plasma membrane (Evans et al., 1991 Finally, it remains possible that p21 ras need not be anchored to the plasma membrane in order to be active. Neither the GTPase activity of p21, nor p21 binding to GTPase activating proteins (GAPs) is determined by the C-terminus that mediates membrane association. GAPs are vital in the physiological regulation of ras (Downward et al., 1990) and may serve as downstream effectors (Bourne et al., 1990) . Moreover, of the two widely present cellular proteins with ras-specific GAP activity, one (the neurofibromatosislinked protein, NF-1) does not show membrane localisation and may mediate different effects of p21 ras from the membrane-associated GAP (Bollag & McCormick, 1991) . Histological methods alone are incapable of distinguishing these last two possibilities, but the unequivocally cytoplasmic location of p21 ras expressed in breast tissue cells stimulates enquiry into the role of this important molecule at this site.
p21 ras in breast pathology
It is tempting to assume that the p21 ras expression observed here is in some way related to cell division. Circumstantial evidence in support of this view includes the stepwise increase in expression with increasing histological deviation from normality as documented here, the highest levels being fund in carcinomas. The age-related decline in p21 expression of normal TDLU epithelium also parallels a decline in proliferation rate (Going et al., 1988b) . It is of course very well established that ras proteins mediate cell proliferation in a variety of other cell types (Feramisco et al., 1984; Mulcahy et al., 1985; Downward et al., 1990) . Nevertheless, p21 expression is also a feature of non-proliferating cells, such as the myoepithelium described here (Joshi et al., 1986 ) and many other cell types (Spandidos & Dimitrov 1985; Chesa et al., 1987) . Ras proteins mediate cellular processes as diverse as neuronal differentiation (Bar-Sagi & Feramisco, 1985) , mast cell degranulation (Bar-Sagi & Gomperts, 1988) , oocyte maturation (Birchmeier et al., 1985) and cell cycle arrest (Franza et al., 1986) . It is therefore premature to conclude that the sole or even major role of the ras expression which we have observed in breast epithelial cells is to promote their proliferation.
Despite uncertainty over its precise role in the breast, there is much evidence to associate p21 ras expression and growth control in the TDLU of both human and animal tissues Strange et al., 1989; Ciardiello et al., 1990; Telang et al., 1990) . This paper emphasises the graded alterations in ras expression in the TDLU epithelium in hyperplasias and carcinoma in situ, and the absence of further change in infiltrative and metastatic lesions. Somewhat similar observations have been made in human colorectal mucosa in the adenoma-carcinoma sequence: both p21 ras expression (Williams et al., 1985; Gallick et al., 1985) and the incidence of Ki-ras mutation (Vogelstein et al., 1988) are predominantly features of adenomas, with no further increase in carcinomas. A dominant common pathway of progression to invasive cancer is less well characterised in the breast (Anderson, 1991) but it may be that here also, a major role of ras expression is to alter epithelial cells in such a way that further genetic changes, associated directly with carcinogenesis, become more probable or more effective. 
